TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a biotechnology startup founded in 2016, with a mission to deliver a cancer-free future for all cancer patients. The company focuses on the intelligent design and efficient delivery of targeted therapeutics, particularly TTX-MC138, which targets microRNA-10b, considered the master regulator of metastatic cell viability in various cancers. Additionally, TransCode has preclinical programs such as TTX-siPDL1 and TTX-siLIN28B for solid tumor treatment, and cancer agnostic programs including TTX-RIGA, TTX-CRISPR, and TTX-mRNA. The company has recently received a $7.25M Post-IPO Equity investment on 18 January 2024, indicating investor confidence in its potential. TransCode's proprietary delivery platform, TTX, enables the transport of targeted therapeutics to cancer cells, offering a solution to the challenge of delivery in cancer therapy. With a rapidly expanding platform of drug candidates and a world-class team, TransCode aims to target a variety of tumor indications with the goal of long-term treatment survival. The company's focus on addressing the highest unmet need in cancer treatment makes it an intriguing prospect for investors in the health care and biotechnology industries.